Despite solid evidence of the success of rotavirus vaccines in saving children from fatal gastroenteritis, more than 82 million infants worldwide still lack access to a rotavirus vaccine. The main barriers to global rotavirus vaccine coverage include cost, manufacturing capacity and suboptimal efficacy in low- and lower-middle income countries. One vaccine candidate with the potential to address the latter is based on the novel, naturally attenuated RV3 strain of rotavirus, RV3-BB vaccine administered in a birth dose strategy had a vaccine efficacy against severe rotavirus gastroenteritis of 94% at 12 months of age in infants in Indonesia. To further develop this vaccine candidate, a well-documented and low-cost manufacturing process is required. A target fully loaded cost of goods (COGs) of ≤3.50percourseofthreedoseswassetbasedonpredictedmarketrequirements.COGsmodellingwasleveragedtodevelopaprocessusingVerocellsincellfactoriesreachinghightiters,reducingorreplacingexpensivereagentsandshorteningprocesstimetomaximiseoutput.Stablecandidateliquidformulationsweredevelopedallowingtwo−yearstorageat2–8°C.Inaddition,theformulationpotentiallyrendersneedlessthepretreatmentofvaccineeswithantacidtoensureadequategastricacidneutralizationforroutineoralvaccination.Asaresult,theformulationallowssmallvolumedosingandreductionofsupplychaincosts.AdoserangingstudyiscurrentlyunderwayinMalawithatwillinformthefinalclinicaldoserequired.Ataclinicaldoseof≤6.3log10FFU,theCOGstargetof≤3.50 per three dose course was met. At a clinical dose of 6.5 log10 FFU, the final manufacturing process resulted in a COGs that is substantially lower than the current average market price, 2.44 USD per dose. The manufacturing and formulation processes were transferred to BioFarma in Indonesia to enable future RV3-BB vaccine production